Saturday 17 October 2026
Export SOLV’s income statement to Excel — free account
Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.
85.81
2.05
−2.33%
Follow SOLV
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
Piotroski F-Score |
5 | — | — | — |
P/E ratio |
8.87 | 24.02 | 10.26 | 10.26 |
Altman Z-Score |
2.22 | 1.47 | — | — |
P/S ratio |
1.66 | 1.39 | 1.69 | 1.69 |
Altman Z″-Score (non-manufacturers) |
2.34 | 1.05 | — | — |
P/FCF ratio |
0.00 | 14.21 | 8.50 | 8.50 |
Beneish M-Score |
(2.07) | (4.40) | — | — |
P/Operating CF |
145.22 | 52.24 | 25.26 | 25.26 |
P/B ratio |
2.73 | 3.87 | 1.18 | 1.18 |
Price to Tangible BV |
0.00 | 0.00 | 6.20 | 6.20 |
EV/Sales |
2.17 | 2.26 | 1.66 | 1.66 |
EV/EBITDA |
6.76 | 11.75 | 6.05 | 6.05 |
EV/Operating CF |
48.92 | 15.77 | 7.11 | 7.11 |
EV/FCF |
(1,805.27) | 23.22 | 8.38 | 8.38 |
Quick Ratio |
0.66 | 0.74 | 0.87 | — |
Current Ratio |
1.23 | 1.20 | 1.46 | — |
Net Debt/EBITDA |
1.56 | 4.56 | (0.09) | 0.00 |
Debt/Assets |
35.22% | 55.41% | 0.00% | 0.00% |
Debt/Equity |
1.00 | 2.71 | 0.00 | 0.00 |
Asset Turnover |
0.58 | 0.58 | 1.18 | 0.00 |
Operating CF/Net income |
0.24 | 2.47 | 1.42 | 1.25 |
Capex/Depreciation |
(0.78) | (0.68) | (0.52) | (0.43) |
Interest Coverage |
6.29 | 2.82 | — | — |
| 38.86% | 6.55% | 0.00% | 0.00% | |
| 10.82% | 3.37% | 19.31% | 0.00% | |
ROIC |
14.81% | 6.34% | 9.22% | 0.00% |
Return on Tangible Assets |
75.94% | 22.09% | 59.88% | 0.00% |
Average Days of Receivables |
51.91 | 54.35 | 58.47 | 0.00 |
Research and Development Expense of Revenue |
8.88% | 9.39% | 9.25% | 9.43% |
Selling, General and Administrative Expense of Revenue |
37.00% | 33.70% | 28.05% | 27.49% |
Intangible Assets out of Total Assets |
0.58 | 0.62 | 0.68 | 0.00 |
Share Based Compensation of Revenue |
1.93% | 1.36% | 0.48% | 0.46% |
Graham Net Nets |
(0.39) | (0.72) | 0.02 | 0.02 |
Graham Number |
76.34 | 32.51 | 108.84 | 0.00 |
Earnings Yield |
11.27% | 4.16% | 9.74% | 9.74% |
Free Cash Flow Yield |
(0.07%) | 7.04% | 11.76% | 11.76% |
Revenue per Share |
47.82 | 47.66 | 47.46 | 47.08 |
Operating CF per Share |
2.12 | 6.84 | 11.09 | 9.72 |
Capex per Share |
(2.18) | (2.19) | (1.68) | (1.45) |
Free Cash Flow per Share |
(0.06) | 4.65 | 9.41 | 8.27 |
Cash per Share |
5.04 | 4.40 | 1.12 | 0.00 |
Shareholders Equity per Share |
29.00 | 17.08 | 67.55 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
29.00 | 17.08 | 67.55 | 0.00 |
Free Cash Flow |
(10.00) | 805.00 | 1,625.00 | 1,428.00 |
Working Capital |
723.00 | 546.00 | 791.00 | — |
Capital Expenditures |
(379.00) | (380.00) | (290.00) | (251.00) |
Net Current Asset Value |
(5,386.00) | (8,249.00) | 242.00 | 0.00 |
EV/EBIT |
8.28 | 18.04 | 8.05 | 8.05 |
Capex to Sales |
0.05 | 0.05 | 0.04 | 0.03 |
Price to Operating Income |
6.33 | 11.04 | 8.17 | 8.17 |
| Other line items | ||||
Depreciation/Fixed assets |
0.37 | 0.34 | 0.39 | 0.00 |
Cash ROIC |
(0.09%) | 6.86% | 13.70% | 0.00% |
Accounts Receivable Turnover |
6.90 | 6.49 | 0.00 | 0.00 |
Accounts Payable Turnover |
5.94 | 6.69 | 0.00 | 0.00 |
Inventory Turnover |
3.81 | 4.02 | 0.00 | 0.00 |
Average Days of Payables |
64.73 | 61.61 | 49.69 | 0.00 |
Days of Inventory on Hand |
100.44 | 96.21 | 89.27 | 0.00 |
Average Receivables |
1,206.50 | 1,271.00 | — | — |
Average Payables |
652.50 | 547.50 | — | — |
Average Inventory |
1,015.50 | 911.00 | — | — |
Average Assets |
14,375.50 | 14,200.00 | 6,971.50 | — |
Average Common Equity |
4,004.50 | 7,312.50 | — | — |
Columns are period end dates